Comerica Bank
CHRS icon

Comerica Bank’s Coherus Oncology CHRS Stock Holding History

Comerica Bank’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-57
Closed -$213 – 3740
2023
Q3 		$213 Buy
+57
New +$263 ﹤0.01% 3758
2022
Q4 		$368K Sell
37,892
-10,708
-22% -$82.4K ﹤0.01% 1886
2022
Q3 		$407K Sell
48,600
-5,980
-11% -$60.5K ﹤0.01% 1863
2022
Q2 		$416K Buy
54,580
+1,125
+2% +$9.78K ﹤0.01% 1902
2022
Q1 		$540K Sell
53,455
-1,738
-3% -$22.1K ﹤0.01% 1833
2021
Q4 		$678K Sell
55,193
-2,385
-4% -$41.7K 0.01% 1742
2021
Q3 		$967K Sell
57,578
-4,790
-8% -$70.2K 0.01% 1707
2021
Q2 		$906K Sell
62,368
-2,104
-3% -$29.8K 0.01% 1771
2021
Q1 		$960K Sell
64,472
-2,417
-4% -$41K 0.01% 1762
2020
Q4 		$1.23M Buy
66,889
+1,236
+2% +$22K 0.01% 1605
2020
Q3 		$1.16M Buy
65,653
+1,368
+2% +$25.4K 0.01% 1470
2020
Q2 		$1.18M Buy
+64,285
New +$1.09M 0.01% 1408

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Comerica Bank's CHRS Position: Q4 2023 in Review

Comerica Bank sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 57 shares — an estimated $213 sold.

Comerica Bank first reported a position in CHRS in Q2 2020 and held it in 12 quarters. The position peaked at $1.23M in Q4 2020. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Comerica Bank reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Comerica Bank sold 57 Coherus Oncology shares in Q4 2023, an estimated $213.
  • Comerica Bank first reported a position in Coherus Oncology in Q2 2020 and held it in 12 quarters.
  • Comerica Bank's Coherus Oncology position peaked at $1.23M in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Comerica Bank's 13F filing for Q4 2023, filed 14 Feb 2024.